ClinicalTrials.gg
RecruitingNCT05983211QuARTS-ALSUpdated Sep 19, 2024

Quantitative and Repetitive TMS in ALS - Recruiting for Stage 2

An interventional study of Repetitive Transcranial Magnetic Stimulation in Amyotrophic Lateral Sclerosis, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Sunnybrook Health Sciences Centre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada — 15 open to participants now, 25 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Canada.

Planned enrollment
64th of 72
15 · median 75
Started
2024
with 8 others
No phase
7 of 82
3 open now
Primary completion
2026-04
later than 1 of 24 live
Registered
63rd of 82
by date
Lead sponsor
3 of 82
Sunnybrook Health Sciences Centre

Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, this one is the 64th largest by planned enrollment of the 72 interventional ones that give a count, is one of 9 that started in 2024, is one of 7 with no phase, reaches primary completion later than 1 of the 24 other live ones, and was the 63rd registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

15 of the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

Stage 1 [Enrolment closed]:

The goal of this open-label pilot clinical trial is to evaluate the safety and feasibility of accelerated, repetitive transcranial magnetic stimulation (rTMS) using continuous theta-burst stimulation (cTBS) in patients with ALS.

Stage 2 [CURRENTLY ENROLLING]:

The goal of this open-label pilot clinical trial is to evaluate the safety, tolerability and target engagement of accelerated, high dose cTBS using TMS in patients with ALS.

Read the detailed description

Stage 1 [Enrolment closed]:

The purpose of this stage is to evaluate the safety, feasibility, and changes in neuronal excitability biomarkers of accelerated repetitive transcranial magnetic stimulation (rTMS) using continuous theta-burst stimulation (cTBS) inhibitory paradigms over M1 in patients with ALS.

Stage 2 [CURRENTLY ENROLLING]:

The purpose of this study is to:

  1. Assess the safety and feasibility of accelerated cTBS treatment with maintenance cTBS treatments in individuals with ALS over a 24-week period.
  2. Assess changes in MR spectroscopy measures of glutamate and GABA, ATP and metabolites markers, and neuronal structure markers, changes in serum neurofilament light chain, and changes in corticohyperexcitability biomarkers measured by single and paired pulse quantitative TMS.
  3. Assess the changes in ALSFRS-R and muscle strength dynamometry.
03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • ALS
  • Repetitive transcranial magnetic stimulation
  • Corticospinal Excitability
  • Motor Neuron Disease
  • MR Spectroscopy
  • Cortical Hyperexcitability
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis with ALS as per the 2020 Gold Coast Criteria;
  • Age ≥ 18 years;
  • Able to provide to study procedures and treatments;
  • Patients are allowed to start or continue the standard of care treatments for ALS. Presently these include oral riluzole, and oral or intravenous edaravone;
  • Able to lie supine without BiPAP or breathing discomfort for at least 1 hour;
  • No to TMS as follow;
  • Metal implants in the head or neck (such as aneurysm clips, vessel stents), implanted medication pump, implanted brain stimulators, pacemaker, cochlear implants, or history of epilepsy. Dental fillings are permitted;
  • Current use of medications or medical conditions that, at the discretion of the Principal Investigator, could potentially increase the risk of seizures or interfere with stage outcomes;
  • On medications that affect TMS measures in a PRN regimen (as needed). Continuous use of these medications on a fixed dose of 30 days prior to first Baseline Visit or after a of 2 weeks is accepted. These medications include, but are not limited to: benzodiazepines, muscle relaxants, tricyclic antidepressants, selective and non-selective serotonin reuptake inhibitors, hypnotics (including anti-histamine drugs) and anticholinergics drugs;
  • History of seizure, convulsion, or epilepsy;

Exclusion criteria

Exclusion Criteria:

  • Known diagnosis of dementia;
  • Definitely or possibly pregnant (if applicable);
  • History of allergy to Ag-AgCl electrode gel (standard neurophysiology electrodes);
  • Unable to tolerate TMS procedures;
  • Lack of MRI brain performed prior to the stage, inability to perform an MRI at baseline due to orthopnea, or:
  • Large body habitus and not fitting comfortably into the scanner;
  • Difficulty laying still for up to 1 hour in the MRI unit or significant claustrophobia;
  • Metallic implants;
  • Any for receiving rTMS treatment as follow:
  • have received rTMS for any previous indication due to the potential compromise of subject blinding;
  • have increased intracranial pressure, a space occupying brain lesion, any history of seizure except those therapeutically induced by ECT or a febrile seizure of infancy, significant head trauma with clear radiological evidence of cerebrovascular injury on imaging;
  • have an intracranial implant or any other metal object within or near the head, excluding the mouth, that cannot be safely removed;
  • have laboratory abnormality, in the opinion of the one of the principal investigators or study physicians;
  • are currently taking more than lorazepam 2 mg daily (or equivalent) or any dose of an anticonvulsant due to the potential to limit rTMS efficacy;
  • Any other clinical condition that, in the opinion of the Site Investigator, would place the subject at increased risk or preclude the subject's full compliance with completion of the stage.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Accelerated cTBS Neuromodulation

    Stage 2 \[CURRENTLY ENROLLING\]: ALS patients receiving an accelerated schedule of continuous theta burst rTMS bilaterally at multiple M1 regions at a regimen of 40 seconds, 1 minute 20 seconds, 2 minutes, or 4 minutes per treatment for up to 8 treatment sessions per day, delivered one per hour, over 5 days. Additional single-day maintenance treatments will follow these 5 days at a frequency of every 2 weeks for 12 weeks, then every 4 weeks for 12 weeks.

    Device: Repetitive Transcranial Magnetic Stimulation

Interventions

  • DeviceRepetitive Transcranial Magnetic Stimulation

    Stage 2 \[CURRENTLY ENROLLING\]: Accelerated rTMS using continuous theta burst stimulation (cTBS) inhibitory paradigms over bilateral M1 including hand, leg, and bulbar regions outputted at 90% of resting motor threshold, using bursts of 3 pulses at 50 Hz. Bursts are repeated at 5 Hz for a total of 600, 1200, 1800, or 3600 pulses over 40 seconds, 1 minute 20 seconds, 2 minutes, or 4 minutes. ALS patients will receive rTMS bilaterally for up to 8 treatment sessions per day, delivered one per hour, over 5 days, followed by single-day maintenance treatments at a frequency of every 2 weeks for 12 weeks, then every 4 weeks for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Safety and Feasibility of cTBS rTMS in patients with ALS

    Incidence of AEs and SAEs after accelerated continuous theta burst stimulation inhibitory intervention in individuals with ALS through the incidence of repetitive TMS treatment related adverse events, serious adverse events, and discontinuations due to adverse events/serious adverse events.

    Time frame: Up to 30 days before compared to during the initial 5 days of cTBS treatment and up to 24 weeks after

Secondary outcomes

  1. Neurofilament light chain (NfL) levels

    Change in concentration of serum neurofilaments from Baseline to Treatment, Week 12, and Week 24

    Time frame: Up to 30 days before compared to the last treatment day, 12 weeks, and 24 weeks after cTBS treatment

  2. ALSFRS-R scores

    \>/= 6-point decline in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) scores from Baseline to Week 12 and Week 24. The ALSFRS-R measures functional ability in ALS with a minimum 0, maximum 48, and where a higher score means a better outcome.

    Time frame: Up to 30 days before compared to 12 and 24 weeks after cTBS treatment

  3. Corticospinal Excitability change measured by quantitative TMS

    Change from baseline in Resting Motor Threshold (RMT), Cortical Silent Period (CSP), Short Intracortical Inhibition (SICI), and Short Intracortical Facilitation (SICF). All measurements use the same units.

    Time frame: Up to 30 days before compared to 12 and 24 weeks after cTBS treatment

  4. Magnetic Resonance Spectroscopy parameters as measured by MRS

    Change from baseline in Glutamate, GABA, neuronal and redox metabolite ratios. All measurements use the same units.

    Time frame: Up to 30 days before compared to the end of treatment week, 5 weeks, 12 weeks, and 24 weeks after cTBS treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Apr 2026, 23 months after the start.

Of 134 non-industry interventional studies with no phase under Amyotrophic Lateral Sclerosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 23 months is below that.

Counting every sponsor, half of 154 studies reached it within 35 months; a quarter within 23 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Aug 9, 2023
StartActual
May 1, 2024
Primary completionEst.
Apr 15, 2026
CompletionEst.
Apr 15, 2027
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05983211
Responsible party
Sponsor
First posted
Aug 9, 2023
Start date
May 1, 2024
Primary completion
Apr 15, 2026 (estimated)
Completion
Apr 15, 2027 (estimated)
Last update
Sep 19, 2024

Study contacts

Agessandro Abrahao, Dr.
Contact
alsresearch@sunnybrook.ca
(416) 480-6100 ext. 687561
Jahan Mookshah
Contact
jahan.mookshah@sunnybrook.ca
416 480-6100 ext. 687561
Agessandro Abrahao, Dr.
principal investigator · Sunnybrook Health Sciences Centre; University of Toronto
Lorne Zinman, Dr.
principal investigator · Sunnybrook Health Sciences Centre; University of Toronto
Sean Nestor, Dr.
principal investigator · Sunnybrook Research Institute; University of Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion